Aaron M Lebeau

List of Publications by Year
in descending order

22 papers	979 citations	623188 14 h-index	642321 23 g-index
24 all docs	24 docs citations	24 times ranked	2056 citing authors

#	Article	IF	Citations
1	The role of CD133 in cancer: a concise review. Clinical and Translational Medicine, 2018, 7, 18.	1.7	257
2	Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Molecular Cancer Therapeutics, 2009, 8, 1378-1386.	1.9	138
3	Targeting uPAR with Antagonistic Recombinant Human Antibodies in Aggressive Breast Cancer. Cancer Research, 2013, 73, 2070-2081.	0.4	83
4	Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity. Cancer Research and Treatment, 2017, 49, 1140-1152.	1.3	68
5	Antagonistic Anti-urokinase Plasminogen Activator Receptor (uPAR) Antibodies Significantly Inhibit uPAR-mediated Cellular Signaling and Migration. Journal of Biological Chemistry, 2010, 285, 26878-26888.	1.6	51
6	Prostate-Specific Antigen Is a "Chymotrypsin-like" Serine Protease with Unique P1 Substrate Specificity. Biochemistry, 2009, 48, 3490-3496.	1.2	42
7	The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates. ELife, 2021, 10, .	2.8	42
8	Imaging a functional tumorigenic biomarker in the transformed epithelium. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 93-98.	3.3	41
9	Non-invasive imaging and cellular tracking of pulmonary emboli by near-infrared fluorescence and positron-emission tomography. Nature Communications, 2015, 6, 8448.	5.8	37
10	The Rational Design of Therapeutic Peptides for Aminopeptidase N using a Substrate-Based Approach. Scientific Reports, 2017, 7, 1424.	1.6	33
11	Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography. Clinical Cancer Research, 2020, 26, 4882-4891.	3.2	32
12	Imaging the Urokinase Plasminongen Activator Receptor in Preclinical Breast Cancer Models of Acquired Drug Resistance. Theranostics, 2014, 4, 267-279.	4.6	31
13	Imaging Active Urokinase Plasminogen Activator in Prostate Cancer. Cancer Research, 2015, 75, 1225-1235.	0.4	25
14	The Molecular Imaging of Natural Killer Cells. Molecular Imaging, 2018, 17, 153601211879481.	0.7	16
15	Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer. Clinical Cancer Research, 2020, 26, 1054-1064.	3.2	15
16	Development of a Cross-Reactive Monoclonal Antibody for Detecting the Tumor Stroma. Bioconjugate Chemistry, 2019, 30, 1466-1476.	1.8	12
17	Protease-Activated Pore-Forming Peptides for the Treatment and Imaging of Prostate Cancer. Molecular Cancer Therapeutics, 2015, 14, 659-668.	1.9	10
18	The identification of a novel antibody for CD133 using human antibody phage display. Prostate, 2018, 78, 981-991.	1.2	9

#	Article	IF	Citations
19	Simultaneous Engagement of Tumor and Stroma Targeting Antibodies by Engineered NK-92 Cells Expressing CD64 Controls Prostate Cancer Growth. Cancer Immunology Research, 2021, 9, 1270-1282.	1.6	9
20	PEG10 Promoterâ€"Driven Expression of Reporter Genes Enables Molecular Imaging of Lethal Prostate Cancer. Cancer Research, 2019, 79, 5668-5680.	0.4	7
21	Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase <i>AMACR</i> promoter for the molecular imaging of prostate cancer. Oncotarget, 2018, 9, 36693-36704.	0.8	4
22	Structural Characterization of a Minimal Antibody against Human APOBEC3B. Viruses, 2021, 13, 663.	1.5	2